Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 11/20 | 0.56 |
| ▸ | P4HA1 | P13674 | 3/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043919 | 1.00 | HCAR3 (0.56) | HCAR3P4HA1P4HTMMIFGABRP | |
| SCHEMBL27688524 | 0.85 | HCAR3 (0.57) | HCAR3P4HA1P4HTMMIFGABRP | |
| SCHEMBL28231895 | 0.85 | HCAR3 (0.53) | HCAR3P4HA1P4HTMMIFGABRP | |
| SCHEMBL11176498 | 0.84 | KCNJ1 (0.44) | HCAR3P4HA1P4HTMMIFHCAR2 | |
| Hydrochloric Acid SCHEMBL18740156 | 0.83 | GABRP (0.52) | HCAR3P4HA1P4HTMMIFGABRP | |
| Hydrochloric Acid SCHEMBL20538973 | 0.83 | GABRP (0.52) | HCAR3P4HA1P4HTMMIFGABRP | |
| SCHEMBL531287 | 0.82 | NNMT (0.55) | — | |
| SCHEMBL31517714 | 0.82 | NNMT (0.55) | — | |
| SCHEMBL12894455 | 0.82 | ALDH1A1 (0.48) | GABRA1GABRB1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25754457 | 0.82 | HCAR3 (0.58) | HCAR3P4HA1P4HTMMIFGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| EP-3334464-B1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | MASSACHUSETTS GEN HOSPITAL (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4229049-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116547278-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20090220430-A1 | Fluorescent Imaging Agents | VISEN MEDICAL, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20080317676-A1 | Biocompatible Fluorescent Imaging Agents | VISEN MEDICAL, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080317676-A1 | Biocompatible Fluorescent Imaging Agents | VISEN MEDICAL, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080267883-A1 | Comprises carboxyl or carbonyl functionalized pyridine moiety; bioconjugation; biocompatability; in vivo optical imaging | VISEN MEDICAL, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267883-A1 | Comprises carboxyl or carbonyl functionalized pyridine moiety; bioconjugation; biocompatability; in vivo optical imaging | VISEN MEDICAL, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080226562-A1 | Biocompatible fluorescent metal oxide nanoparticles | VISEN MEDICAL, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1852431-A1 | OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | HCAR3 2578/4885P4HA1 2563/4885P4HTM 1805/4885 |
| US-20080317676-A1 | Biocompatible Fluorescent Imaging Agents | CD47, FIBP, CD68 | HCAR3 126/4885P4HA1 2433/4885P4HTM 2624/4885 |
| US-20080226562-A1 | Biocompatible fluorescent metal oxide nanoparticles | MACO1, CD68, CD63 | HCAR3 670/4885P4HA1 1403/4885P4HTM 1454/4885 |
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | C3AR1, C5AR1, C5AR2 | HCAR3 28/4885P4HA1 1212/4885P4HTM 433/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | HCAR3 714/4885P4HA1 1292/4885P4HTM 1526/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | HCAR3 1359/4885P4HA1 1342/4885P4HTM 1987/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | HCAR3 1681/4885P4HA1 1340/4885P4HTM 2727/4885 |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | CYP11B2, OAT, CYP27A1 | HCAR3 1913/4885P4HA1 2402/4885P4HTM 1684/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | HCAR3 1714/4885P4HA1 4676/4885P4HTM 4792/4885 |
| US-20090220430-A1 | Fluorescent Imaging Agents | DNPEP, FURIN, MME | HCAR3 913/4885P4HA1 965/4885P4HTM 984/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | HCAR3 444/4885P4HA1 1065/4885P4HTM 1057/4885 |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HCAR3 310/4885P4HA1 924/4885P4HTM 1049/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | HCAR3 444/4885P4HA1 1065/4885P4HTM 1057/4885 |
| US-20080267883-A1 | Comprises carboxyl or carbonyl functionalized pyridine moiety; bioconjugation; biocompatability; in vivo optical imaging | PAICS, PC, CBR3 | HCAR3 128/4885P4HA1 1432/4885P4HTM 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.